Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04715997
Other study ID # GX-19N-HV-002
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 30, 2020
Est. completion date June 30, 2022

Study information

Verified date November 2021
Source Genexine, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.


Description:

This clinical study is phase 1/2a clinical trial to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive vaccine by intramuscularly administration in healthy volunteers. Phase 1 of this study is designed as single arm, open-labeled and a total of 20 subjects will be enrolled. Phase 2a of study is designed as randomized, double-blind, placebo controlled and a total of 150 subjects are planned to be enrolled.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 170
Est. completion date June 30, 2022
Est. primary completion date July 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Able and willing to comply with all study procedures and voluntarily signs informed consent form - Healthy adult male or female aged 19-55 years - Willing to provide specimens such as blood and urine during the study, including end of study visit. Exclusion Criteria: - Immunosuppresion including immunodeficiency disease or family history - Any history of malignant disease within the past 5 years - Scheduled to undergo any surgery or dental treatment during the study - Having received immunoglobulin or blood-derived drugs or being expected to be administered within 3 months prior to administration. - Having relied on antipsychotic drugs and narcotic analgesics within 6 months before administration - Positive of serology test at screening - Suspected of drug abuse or a history within 12 months prior to administration - Active alcohol use or history of alcohol abuse - Serious adverse reaction to a drug containing GX-19N or other ingredients of the same categories or to a vaccine or antibiotic, nonsteroidal anti-inflammatory disease control, etc. or an allergic history - History of hypersensitivity to vaccination such as Guillain-Barre syndrome - Those who have or with a history of disease corresponding to other hepatobiliary, kidneys, nervous systems (middle or peripheral), respiratory machines (e.g. asthma, pneumonia, etc., endocrine systems (uncontrolled diabetes, hyperlipidemia, etc.) and cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension), blood tumors, urinary machines, mental, musculoskeletal systems, immune system (rheumatoid arthritis, systemic arthritis, mumps, immunodeficiency disease) - Having hemophilia at risk of causing serious bleeding when injected intramuscularly or receiving anticoagulants - Subjects who have been contact with COVID-19 infections in the past prior to administration, have been classified as COVID-19 confirmed patients, medical patients or patients with symptoms or have been identified with SARS and MERS infection history in the past - Acute fever, cough, difficulty breathing, chills, muscle aches, headache, sore throat, loss of smell, or loss of taste within 72 hours prior to administration - Other vaccination history within 28 days prior to the administration or being scheduled to be inoculated during the study - History of having taken immunosuppressant or Immune modifying drug within 3 months prior to administration - Having participated and had clinical trial drug administration in another clinical trial or biological equivalence study within 6 months prior to the administration - Pregnant or breastfeeding female, however, those are allowed to participate in the study only if they stop breastfeeding before participation (fertile femaleā€  must be negative in serum pregnancy test at screening - Fertile female who do not agree to use effective contraception methods (condoms, contraceptive diaphragm, intrauterine contraceptive devices) during the study - Any other clinically significant medical or psychiatric finding which is considered inappropriate by investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GX-19N
DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
Placebo
Normal saline

Locations

Country Name City State
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Hanyang University Hospital Seoul
Korea, Republic of KyungHee University Medical Center Seoul
Korea, Republic of Severance Hospital Seoul
Korea, Republic of Ajou University Hospital Suwon

Sponsors (1)

Lead Sponsor Collaborator
Genexine, Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline in Antigen-specific IFN-gamma Cellular Immune Response Antigen-specific IFN-? T cell immune response assessed after vaccination Through 1 year post vaccination
Primary Incidence of Solicited Adverse Events solicited local and systemic AEs after vaccination Through 1 year post vaccination
Primary Incidence of Unsolicited Adverse Events unsolicited AEs after vaccination Through 1 year post vaccination
Primary Incidence of Serious Adverse Events percentage of subjects with SAEs Through 1 year post vaccination
Secondary GMT of Antigen-specific Binding Antibody Titers Geometric mean titer (GMT) of antigen-specific binding antibody after vaccination Through 1 year post vaccination
Secondary GMFR of Antigen-specific Binding Antibody Titers Geometric mean fold rise (GMFR) of antigen-specific binding antibody after vaccination Through 1 year post vaccination
Secondary Percentage of Subjects Who Seroconverted After Vaccination Seroconversion defines when FRNT50 is detected more than four times from the baseline after vaccination Through 1 year post vaccination
Secondary GMT and GMFR of Neutralizing Antibody Level Geometric mean titer (GMT) and Geometric mean fold rise (GMFR) of neutralizing antibody after vaccination Through 1 year post vaccination
Secondary GMFR of Neutralizing Antibody Level Geometric mean fold rise (GMFR) of neutralizing antibody after vaccination Through 1 year post vaccination
Secondary GMSN and GMFR of Spot Forming Unit (SFU) detected by IFN-gamma ELISPOT assay Geometric mean spot numbers (GMSN) and Geometric mean fold rise (GMFR) of SFU after vaccination Through 1 year post vaccination
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A